DM medication list: Complete reference for clinicians

Key takeaways

A DM medication list organizes every major diabetes drug by class, with generic and brand names, mechanism of action, and monitoring requirements.

Metformin is first-line oral therapy for most type 2 patients. Insulin stays the foundation of type 1 care and of advanced type 2 disease.

GLP-1 receptor agonists and SGLT-2 inhibitors now lead second-line choice, and most type 2 patients end up on combination therapy.

Every entry needs a monitoring line as well as a dose, since B12, eGFR, and A1C intervals are what reviews are built on.

Practice management software like Pabau stores the regimen in the patient record, then brings each patient back for the review that checks it.

A DM medication list is the single reference that sets out every diabetes drug by class, with its dose range, mechanism, and monitoring requirements.

The classes it covers are insulin, biguanides, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, and fixed-dose combinations. Metformin is first-line oral therapy for most type 2 patients, and insulin remains the foundation of type 1 care.

New approvals arrive and dosing parameters shift, so the list needs a review cadence of its own. This guide covers how each class works and gives an A1C-to-intensification table. It also sets out the fields every entry should record, and how to run a review from it.

What is a DM medication list, and why do clinicians need one?

A DM medication list is a clinical reference that consolidates the major diabetes medications into one scannable document, organized by drug class. It saves switching between sources to check a brand-name equivalent, a dose range, or which agents carry cardiovascular and renal benefits.

Take a new type 2 patient with chronic kidney disease and an A1C of 8.2%. The clinician needs to know which second-line agents are safe in renal impairment, what dose adjustments apply, and which drugs protect the kidney. Without a list, that means searching three separate sources mid-consultation.

Practices also use the list for clinical documentation, patient education, and medication reconciliation at reviews. The same document supports an audit of the medication record, confirming that drug selection and monitoring were both appropriate.

Diabetes medication classes and how they work

Every diabetes medication sits in a class with its own mechanism, target population, and clinical context. Knowing the categories is what makes a logical treatment sequence and a sensible combination regimen possible.

Insulin types

Insulin remains the foundational therapy for type 1 diabetes and advanced type 2 disease. Modern regimens combine rapid-acting insulin (lispro, aspart, glulisine), short-acting regular insulin, intermediate-acting NPH, and long-acting basal insulin (glargine, degludec, detemir).

Onset, peak, and duration all vary by formulation. They also vary by route, whether that is subcutaneous injection, an insulin pump, or inhaled rapid-acting insulin.

Metformin and biguanides

Metformin is first-line oral therapy for most type 2 patients, working through hepatic glucose suppression and improved insulin sensitivity. Standard dosing runs 500 to 2,550 mg daily in divided doses, and extended-release formulations allow once-daily dosing.

It is contraindicated below an eGFR of 30 mL/min/1.73 m², and starting it between 30 and 45 is not recommended. Gastrointestinal upset is the common side effect, and gradual titration keeps it manageable.

GLP-1 receptor agonists

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide) enhance postprandial insulin secretion and slow gastric emptying. They deliver strong A1C reduction of roughly 1.5 to 2.5%, alongside cardiovascular event reduction and weight loss. That combination matters most in patients with obesity.

Ozempic and Mounjaro are approved for glycemic control, while Wegovy and Zepbound are approved for weight management. Dosing is subcutaneous, once weekly or once daily depending on the agent.

SGLT-2 inhibitors

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) promote urinary glucose excretion, through a mechanism that does not depend on insulin secretion. They give A1C reduction of about 0.5 to 1.2%, modest weight loss, and lower blood pressure.

The cardiovascular and renal protection matters most, and it is documented in the EMPA-REG OUTCOME, CREDENCE, and DAPA-CKD trials. These are oral tablets, well tolerated, with low hypoglycemia risk.

DPP-4 inhibitors

DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) prolong glucagon-like peptide-1 activity by blocking its breakdown. They offer modest A1C reduction of 0.5 to 1%, stay weight-neutral, and carry minimal hypoglycemia risk. Dosing is oral, once or twice daily depending on the agent.

Sulfonylureas

Sulfonylureas (glipizide, glyburide, glimepiride) stimulate pancreatic beta cells to release insulin directly. These older agents reduce A1C substantially, but they carry hypoglycemia risk and modest weight gain. They are usually reserved for patients who cannot tolerate or afford newer agents, or where glycemic control is needed quickly.

Thiazolidinediones

Thiazolidinediones (pioglitazone, rosiglitazone) improve insulin sensitivity at tissue level. They carry FDA warnings for fluid retention, worsening heart failure, and higher fracture rates with long-term use. A1C reduction is modest, at roughly 0.5 to 1.5%. That risk profile is why they are prescribed less often now.

Meglitinides and alpha-glucosidase inhibitors

Meglitinides (repaglinide, nateglinide) trigger a rapid, short-lived insulin release and are taken before meals, mainly for postprandial hyperglycemia. Alpha-glucosidase inhibitors (acarbose, miglitol) slow carbohydrate absorption in the small intestine and blunt the same post-meal spikes. Both classes are less potent than first-line agents.

The A1C reduction each class delivers varies widely, and the trade-off attached to it usually decides the prescription.

Combination diabetes medications

Fixed-dose combinations consolidate a multi-agent regimen into one product, which makes adherence easier for the patient. Common products pair metformin with a sulfonylurea (Metaglip) or a DPP-4 inhibitor (Janumet). Others pair a GLP-1 agonist with basal insulin (Xultophy), or an SGLT-2 inhibitor with a DPP-4 inhibitor (Glyxambi).

Each one turns several pills into a single formulation while still allowing dose titration. Record the combination product and its components, so the next clinician can see both.

A1C targets and medication selection: Quick reference

American Diabetes Association guidelines recommend an individualized A1C target, typically 7% for most adults. Aim higher for patients with limited life expectancy or high hypoglycemia risk, and lower for motivated younger patients.

An A1C conversion chart is useful where the patient tracks estimated average glucose instead. The table below maps A1C ranges to intensification steps and the agents preferred in each clinical context.

This framework follows the ADA Standards of Care. Medication choice rests on A1C alongside cardiovascular disease, chronic kidney disease, body weight, hypoglycemia risk, and cost. Practices running medication verification workflows can record those factors in the treatment plan the patient takes home.

Key clinical insight: GLP-1 receptor agonists and SGLT-2 inhibitors have changed how type 2 diabetes is sequenced. They are now the preferred add-on for patients with established cardiovascular disease, heart failure, or chronic kidney disease. The evidence behind that is the demonstrated reduction in mortality and hospitalization.

What each entry on the list should record

A medication list is only useful at the point of care if every entry carries the same fields. The template uses seven, and each one answers a question that comes up during a review.

• Generic name. The name the prescription and the record are both built on.
• Brand names. What the patient calls the drug, which is how most reconciliation errors get caught.
• Drug class. The grouping that governs what you can safely add next.
• Mechanism of action. One line, enough to explain the drug to the patient in plain terms.
• Typical dose range. Starting dose, maximum dose, and whether an extended-release form exists.
• Cautions and contraindications. Renal thresholds, heart failure warnings, and hypoglycemia risk.
• Monitoring. What to check and how often, such as eGFR, vitamin B12, or A1C.

Monitoring is the field that keeps a review honest, and it is the easiest one to omit. A metformin entry without a B12 line is a deficiency nobody looks for until the patient reports numbness.

How to use the list at a medication review

Reviews should run every three to six months for patients on a new regimen, and at least annually for stable patients. Work through the list in the same order each time.

1. Reconcile what the patient is actually taking against what the record says, using brand names as the prompt.
2. Check the latest A1C against the patient’s individualized target, then find the matching row in the table above.
3. Re-check eGFR, weight, and blood pressure, since each one can rule an agent in or out.
4. Ask about side effects by name, particularly gastrointestinal symptoms and any hypoglycemic episodes.
5. Confirm the monitoring due for each drug, and book the bloods before the patient leaves.
6. Record the decision and the reason for it, so the next clinician sees why the regimen looks the way it does.

Reading the patient’s blood glucose log alongside the A1C shows whether the problem is fasting or postprandial. That distinction points to a different agent than the A1C number alone would.

Practices that book the next review before the patient leaves catch side effects and non-response earlier. Automated reminders cut the number of missed follow-ups.

How Pabau keeps diabetes medication reviews in one record

Most practices keep the regimen in one place, the monitoring dates in another, and the A1C history in a third. Reconciliation then happens from memory during a ten-minute appointment.

Practice management software like Pabau holds all three in the patient record. Digital medication intake forms capture medication history, allergies, and contraindications at every visit. The list the clinician reads is the one the patient just confirmed.

Pabau Scribe, our AI scribe, writes the medication summary into the note as the consultation happens. Practices running diabetes care alongside weight management often standardize on weight loss clinic software that holds both programs in one record.

The template can be attached to that record as a reference document, so the whole team works from the same version. The outcome is a shorter review that produces a better record, with the next monitoring date already booked.

Keep every diabetes medication review in one record

Pabau captures medication history at intake, stores the monitoring due for each drug, and brings the patient back on the right day. Your team reviews the regimen from one record instead of three.

Book a demo

Conclusion

A structured DM medication list is the reference a diabetes care program runs on. Whether the patient has type 1, type 2, or gestational diabetes, the clinician needs mechanisms, dose ranges, contraindications, and monitoring in one place.

Download the free template above and adjust it to the agents and dosing conventions your practice prefers. The one field worth guarding is monitoring, because that is what turns a drug list into a care plan.

The list earns its keep once it lives inside the record rather than beside it. Book a demo to see how Pabau supports diabetes care from intake through to the next review.

Continue your research

Want the prescribing context behind the GLP-1 surge? GLP-1 statistics collects the prescribing, adherence and outcome figures in one place.

Patients asking what to eat alongside the drugs? Type 2 diabetes diet food list gives them a printable list to take home.

Screening before diabetes is established? Insulin resistance levels chart sets out the thresholds that decide when to treat.

Deciding between lifestyle change and a prescription? Lifestyle vs pharmacologic interventions works through when each one is the better first move.

Frequently asked questions